PSTV (Plus Therapeutics) Beginning Cash Position: $8.76 Mil (As of Mar. 2026)


PSTV Plus Therapeutics Inc PSTV
28 GF Score
Price $4.00
! 2 Warning Signs
View Full Analysis

What is Plus Therapeutics Beginning Cash Position?

Plus Therapeutics PSTV 28 Beginning Cash Position is $8.76 Mil as of Mar. 2026. GuruFocus rates PSTV with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Plus Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $8.76 Mil.

Plus Therapeutics's quarterly Beginning Cash Position increased from Sep. 2025 ($2.23 Mil) to Dec. 2025 ($13.29 Mil) but then declined from Dec. 2025 ($13.29 Mil) to Mar. 2026 ($8.76 Mil).

Plus Therapeutics's annual Beginning Cash Position declined from Dec. 2023 ($18.12 Mil) to Dec. 2024 ($8.55 Mil) and declined from Dec. 2024 ($8.55 Mil) to Dec. 2025 ($0.08 Mil).

Plus Therapeutics Beginning Cash Position Related Terms

Plus Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Plus Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Plus Therapeutics Beginning Cash Position Chart

Plus Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.35 18.40 18.12 8.55 0.08

Plus Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 9.87 2.23 13.29 8.76
PSTV
28GF Score
Plus Therapeutics Inc PSTV
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Plus Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $8.76 Mil mean?
Plus Therapeutics (PSTV) has a Beginning Cash Position of $8.76 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Plus Therapeutics and its competitors.
Is Plus Therapeutics' Beginning Cash Position too high?
Plus Therapeutics' current Beginning Cash Position is $8.76 Mil. Overall, Plus Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Plus Therapeutics' Beginning Cash Position compare to KYNB and VTGN?
Plus Therapeutics' Beginning Cash Position of $8.76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Plus Therapeutics and its competitors. Plus Therapeutics's current Beginning Cash Position is $8.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plus Therapeutics stock overvalued right now?
Plus Therapeutics (PSTV) has a current Beginning Cash Position of $8.76 Mil. The current Beginning Cash Position is $8.76 Mil. Plus Therapeutics' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Plus Therapeutics (PSTV), the current Beginning Cash Position is $8.76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Plus Therapeutics Business Description

Other Exchanges XMP1:Germany
Address 6420 Levit Green Boulevard, Suite 210, Houston, TX, USA, 77021
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
28GF Score

Get the complete analysis for PSTV

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.00
Price